BIOMAT Database Logo BIOMAT Database Logo

Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). 1997

G Socié, and J Y Cahn, and J Carmelo, and J P Vernant, and J P Jouet, and N Ifrah, and N Milpied, and M Michallet, and B Lioure, and J L Pico, and F Witz, and L Molina, and A Fischer, and V J Bardou, and E Gluckman, and J Reiffers
Service de Greffe de Moëlle, Hôpital Saint Louis, Paris, France.

Increasing numbers of patients are surviving after allogeneic bone marrow transplantation and are therefore at risk for developing late complications. Among these complications, avascular necrosis of bone has been reported, but only two single-centre studies included sufficient patients to enable analysis of the risk factors for developing avascular necrosis. In this multicentre retrospective study the aim was to assess risk factors for this complication in a large number of patients. The population consisted of 4388 patients, recorded in the Societe Francaise de Greffe de Moelle (SFGM) data base, who had undergone a single allogeneic bone marrow transplant between January 1974 and December 1993. 77 patients developed avascular necrosis leading to a 4.3% projected incidence at 5 years. Symptoms developed 2-132 months after transplantation. In these 77 patients a mean of 1.87 joints per patient were affected (range 1-7). The hip joint was the most often affected (88% of patients) and 48% of the patients required joint replacement. All but two patients received steroids for acute and/or chronic graft-versus-host disease (GvHD) over a mean period of 15 months. In univariate analysis, among eight factors tested as risk factors for developing avascular necrosis, six were shown to be linked to an increased risk: older age, diagnosis of aplastic anaemia or acute leukaemia, an irradiation-based conditioning regimen, type of GvHD prophylaxis regimens, acute and chronic GvHD. In multivariate logistic regression analysis, five factors remained significantly associated with an increased risk for developing avascular necrosis: chronic GvHD (odds ratio (OR) 3.52), acute GvHD (OR 3.73), age > 16 years (OR 5.81), aplastic anaemia (OR 3.90), and acute leukaemia (OR 1.72). Avascular necrosis is not a rare late complication of allogeneic bone marrow transplantation causing significant morbidity. In this study, older age, initial diagnosis, and GvHD and/or its treatment with steroids emerged as significant risk factors.

UI MeSH Term Description Entries
D008297 Male Males
D010020 Osteonecrosis Death of a bone or part of a bone, either atraumatic or posttraumatic. Aseptic Necrosis of Bone,Avascular Necrosis of Bone,Kienbock Disease,Necrosis, Aseptic, of Bone,Necrosis, Avascular, of Bone,Bone Necrosis,Kienbock's Disease,Kienboeck Disease,Kienboeck's Disease,Bone Aseptic Necrosis,Bone Avascular Necrosis,Bone Necroses,Kienboecks Disease,Necroses, Bone,Necrosis, Bone,Osteonecroses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

G Socié, and J Y Cahn, and J Carmelo, and J P Vernant, and J P Jouet, and N Ifrah, and N Milpied, and M Michallet, and B Lioure, and J L Pico, and F Witz, and L Molina, and A Fischer, and V J Bardou, and E Gluckman, and J Reiffers
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
November 2003, Bone marrow transplantation,
G Socié, and J Y Cahn, and J Carmelo, and J P Vernant, and J P Jouet, and N Ifrah, and N Milpied, and M Michallet, and B Lioure, and J L Pico, and F Witz, and L Molina, and A Fischer, and V J Bardou, and E Gluckman, and J Reiffers
Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM).
May 1997, Bone marrow transplantation,
G Socié, and J Y Cahn, and J Carmelo, and J P Vernant, and J P Jouet, and N Ifrah, and N Milpied, and M Michallet, and B Lioure, and J L Pico, and F Witz, and L Molina, and A Fischer, and V J Bardou, and E Gluckman, and J Reiffers
Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle.
July 1996, Blood,
G Socié, and J Y Cahn, and J Carmelo, and J P Vernant, and J P Jouet, and N Ifrah, and N Milpied, and M Michallet, and B Lioure, and J L Pico, and F Witz, and L Molina, and A Fischer, and V J Bardou, and E Gluckman, and J Reiffers
Allogeneic bone marrow transplantation remains an efficient consolidation for adults with acute myeloid leukemia even when performed very soon after diagnosis (< 100 days). The SFGM (Société Française de Greffe de Moelle.
June 1995, Leukemia,
G Socié, and J Y Cahn, and J Carmelo, and J P Vernant, and J P Jouet, and N Ifrah, and N Milpied, and M Michallet, and B Lioure, and J L Pico, and F Witz, and L Molina, and A Fischer, and V J Bardou, and E Gluckman, and J Reiffers
Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
February 2015, Bone marrow transplantation,
G Socié, and J Y Cahn, and J Carmelo, and J P Vernant, and J P Jouet, and N Ifrah, and N Milpied, and M Michallet, and B Lioure, and J L Pico, and F Witz, and L Molina, and A Fischer, and V J Bardou, and E Gluckman, and J Reiffers
Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
July 1997, Bone marrow transplantation,
G Socié, and J Y Cahn, and J Carmelo, and J P Vernant, and J P Jouet, and N Ifrah, and N Milpied, and M Michallet, and B Lioure, and J L Pico, and F Witz, and L Molina, and A Fischer, and V J Bardou, and E Gluckman, and J Reiffers
Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
June 1995, Bone marrow transplantation,
G Socié, and J Y Cahn, and J Carmelo, and J P Vernant, and J P Jouet, and N Ifrah, and N Milpied, and M Michallet, and B Lioure, and J L Pico, and F Witz, and L Molina, and A Fischer, and V J Bardou, and E Gluckman, and J Reiffers
Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors.
March 1994, British journal of haematology,
G Socié, and J Y Cahn, and J Carmelo, and J P Vernant, and J P Jouet, and N Ifrah, and N Milpied, and M Michallet, and B Lioure, and J L Pico, and F Witz, and L Molina, and A Fischer, and V J Bardou, and E Gluckman, and J Reiffers
Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
March 2016, Bone marrow transplantation,
G Socié, and J Y Cahn, and J Carmelo, and J P Vernant, and J P Jouet, and N Ifrah, and N Milpied, and M Michallet, and B Lioure, and J L Pico, and F Witz, and L Molina, and A Fischer, and V J Bardou, and E Gluckman, and J Reiffers
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.
February 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!